模态天然产品panepocyclinol A通过二共价修饰抑制STAT3
Li Li1,2,3, Yuezhou Wang1,2,3, Yiqiu Wang4
1State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, China.
Acta pharmaceutica Sinica. B
|March 5, 2025
概括
帕内波环醇A (PecA) 是一种新的STAT3抑制剂,具有强大的抗瘤作用. 这种二次化合物破坏了STAT3DNA结合和转录活动,为像T细胞淋巴瘤这样的癌症提供了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 双蛋白相互作用对细胞功能至关重要,可以作为药物开发的目标.
- STAT3 (信号转换器和转录3激活器) 是细胞生长和存活的关键调节器,在癌症中经常失调.
研究的目的:
- 从自然产品系列中识别新型STAT3抑制剂.
- 描述帕内波环林醇A (PecA) 的作用机制和抗瘤功效.
主要方法:
- 一个二维自然产品库的选.
- 生物化学测试以评估STAT3抑制 (DNA结合,转录活性).
- 分子动力学模拟以阐明结合相互作用.
- 在体外和体内实验室的疗效研究中,对形大T细胞淋巴瘤模型进行了研究.
主要成果:
- 帕内波环素A (PecA) 被确定为一种强效和选择性的STAT3抑制剂.
- 佩卡通过其迈克尔受体在单独的STAT3单体中交叉链接C712/C718残留物来起作用.
- 这种二共价修饰破坏了STAT3二分化,取消了DNA结合,并抑制了转录活动.
- PecA在体外和体内表现出显著的抗瘤疗效,特别是在具有激活STAT3或STAT3Y640F的模型中.
结论:
- PecA代表了一种新型的二共价抑制剂,向二维STAT3.
- 它独特的破坏STAT3功能机制为STAT3依赖性癌症提供了一个有前途的治疗途径.
- PecA显示出治疗形大T细胞淋巴瘤的显著潜力.
相关概念视频
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K


